113 related articles for article (PubMed ID: 30203418)
1. Iron overload is correlated with impaired autologous stem cell mobilization and survival in acute myeloid leukemia.
Alva LC; Bacher U; Seipel K; Mansouri Taleghani B; Mueller BU; Novak U; Pabst T
Transfusion; 2018 Oct; 58(10):2365-2373. PubMed ID: 30203418
[TBL] [Abstract][Full Text] [Related]
2. An antecedent diagnosis of refractory anemia with excess blasts has no influence on mobilization of peripheral blood stem cells and hematopoietic recovery after autologous stem cell transplantation in acute myeloid leukemia.
Viola A; Falco C; D'Elia R; D'Amico MR; Vicari L; Tambaro FP; Correale P; Laudati D; Palmieri S; Ferrara F
Eur J Haematol; 2007 Jan; 78(1):41-7. PubMed ID: 17042770
[TBL] [Abstract][Full Text] [Related]
3. Transfusion-associated iron overload as a predictive factor for poor stem cell mobilization in patients with haematological malignancies.
Park IH; Kim Y; Kim JS; Cheong JW; Song JW; Min YH
Transfus Med; 2008 Apr; 18(2):97-103. PubMed ID: 18399843
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting stem cell mobilization for autologous hematopoietic stem cell transplantation.
Ozkurt ZN; Yegin ZA; Suyani E; Aki SZ; Acar K; Yagci M; Sucak GT
J Clin Apher; 2010; 25(5):280-6. PubMed ID: 20623783
[TBL] [Abstract][Full Text] [Related]
5. Presence of FLT3 mutations does not impair stem cell mobilization and feasibility of autologous peripheral blood stem cell transplantation in acute myeloid leukemia.
Ferrara F; Palmieri S; Pollio F; Lo Pardo C; Graziano D; Celentano M; D'Amico MR; Vicari L; Izzo B; Pane F
Biol Blood Marrow Transplant; 2006 Sep; 12(9):981-6. PubMed ID: 16920565
[TBL] [Abstract][Full Text] [Related]
6. Age has no influence on mobilization of peripheral blood stem cells in acute myeloid leukemia.
Ferrara F; Viola A; Copia C; Falco C; D'Elia R; Tambaro FP; Correale P; D'Amico MR; Vicari L; Palmieri S
Hematol Oncol; 2007 Jun; 25(2):84-9. PubMed ID: 17361983
[TBL] [Abstract][Full Text] [Related]
7. Influential factors for the collection of peripheral blood stem cells and engraftment in acute myeloid leukemia patients in first complete remission.
Lee J; Lee MH; Park KW; Kang JH; Im DH; Kim K; Lee SH; Kim WS; Park J; Jung CW; Parka K
Int J Hematol; 2005 Apr; 81(3):258-63. PubMed ID: 15814338
[TBL] [Abstract][Full Text] [Related]
8. Transfusion-associated iron overload as an adverse risk factor for transplantation outcome in patients undergoing reduced-intensity stem cell transplantation for myeloid malignancies.
Kim YR; Kim JS; Cheong JW; Song JW; Min YH
Acta Haematol; 2008; 120(3):182-9. PubMed ID: 19129689
[TBL] [Abstract][Full Text] [Related]
9. Impact of gemtuzumab ozogamicin consolidation on hematopoietic stem cells (HSCs) mobilization in AML: analysis of 20 patients.
Perrone S; Capria S; Bernardi M; Marchesi F; Ortu La Barbera E; Trisolini SM; Minotti C; Shafii Bafti M; Scerpa MC; Mulé A; Ciceri F; Martelli M; Cimino G
Ann Hematol; 2023 Apr; 102(4):769-775. PubMed ID: 36795117
[TBL] [Abstract][Full Text] [Related]
10. Mobilization-driven postconsolidation therapy in elderly patients with acute myeloid leukemia: feasibility and efficacy of autologous stem cell transplantation versus low-dose gemtuzumab ozogamicin.
Capelli D; Chiarucci M; Poloni A; Saraceni F; Mancini G; Trappolini S; Troiani E; Montanari M; Scortechini I; Offidani M; Rupoli S; Scortechini AR; Gini G; Discepoli G; Leoni P; Olivieri A
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1399-406. PubMed ID: 24880020
[TBL] [Abstract][Full Text] [Related]
11. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.
Kim IH; Moon JH; Lim SN; Sohn SK; Kim HG; Lee GW; Kim YS; Lee HS; Kwon KY; Kim SH; Park KT; Chung JS; Lee WS; Lee SM; Hyun MS; Kim H; Ryoo HM; Bae SH; Joo YD
Transfusion; 2015 Jul; 55(7):1613-20. PubMed ID: 25764017
[TBL] [Abstract][Full Text] [Related]
13. Autografting as a risk factor for persisting iron overload in long-term survivors of acute myeloid leukaemia.
Butt NM; Clark RE
Bone Marrow Transplant; 2003 Nov; 32(9):909-13. PubMed ID: 14561992
[TBL] [Abstract][Full Text] [Related]
14. Impact of iron overload by transfusion on survival and leukemia transformation of myelodysplastic syndromes in a single center of China.
Wang Y; Huang L; Hua Y; Liu H; Jiang H; Wang H; Zhang W; Fu R; Shao Z
Hematology; 2021 Dec; 26(1):874-880. PubMed ID: 34753406
[TBL] [Abstract][Full Text] [Related]
15. The relapse risk of AML patients undergoing autologous transplantation correlates with the stem cell mobilizing potential.
von Grünigen I; Raschle J; Rüsges-Wolter I; Taleghani BM; Mueller BU; Pabst T
Leuk Res; 2012 Nov; 36(11):1325-9. PubMed ID: 22727508
[TBL] [Abstract][Full Text] [Related]
16. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
Visani G; Lemoli R; Tosi P; Martinelli G; Testoni N; Ricci P; Motta M; Gherlinzoni F; Leopardi G; Pastano R; Rizzi S; Piccaluga P; Isidori A; Tura S
Bone Marrow Transplant; 1999 Sep; 24(5):467-72. PubMed ID: 10482929
[TBL] [Abstract][Full Text] [Related]
17. Autologous Hematopoietic Stem Cell Transplantation for Adults With Acute Myeloid Leukemia.
Cioch M; Jawniak D; Wach M; Mańko J; Radomska K; Borowska H; Szczepanek A; Hus M
Transplant Proc; 2016 Jun; 48(5):1814-7. PubMed ID: 27496498
[TBL] [Abstract][Full Text] [Related]
18. Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65 years.
Heini AD; Berger MD; Seipel K; Taleghani BM; Baerlocher GM; Leibundgut K; Banz Y; Novak U; Pabst T
Leuk Res; 2017 Feb; 53():28-34. PubMed ID: 27978458
[TBL] [Abstract][Full Text] [Related]
19. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis.
Helbig G; Koclęga A; Woźniczka K; Kopera M; Kyrcz-Krzemień S
Pathol Oncol Res; 2018 Jul; 24(3):469-475. PubMed ID: 28660547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
